JP2018514210A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514210A5 JP2018514210A5 JP2017555780A JP2017555780A JP2018514210A5 JP 2018514210 A5 JP2018514210 A5 JP 2018514210A5 JP 2017555780 A JP2017555780 A JP 2017555780A JP 2017555780 A JP2017555780 A JP 2017555780A JP 2018514210 A5 JP2018514210 A5 JP 2018514210A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- domain peptide
- agent
- momp
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 66
- 210000004027 cell Anatomy 0.000 claims description 47
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 16
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 16
- 102000008186 Collagen Human genes 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 210000002744 extracellular matrix Anatomy 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 230000035945 sensitivity Effects 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 6
- FYNNIUVBDKICAX-UHFFFAOYSA-M 1,1',3,3'-tetraethyl-5,5',6,6'-tetrachloroimidacarbocyanine iodide Chemical group [I-].CCN1C2=CC(Cl)=C(Cl)C=C2N(CC)C1=CC=CC1=[N+](CC)C2=CC(Cl)=C(Cl)C=C2N1CC FYNNIUVBDKICAX-UHFFFAOYSA-M 0.000 claims description 4
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 claims description 4
- 101150082208 DIABLO gene Proteins 0.000 claims description 4
- 102000016359 Fibronectins Human genes 0.000 claims description 4
- 108010067306 Fibronectins Proteins 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 230000002438 mitochondrial effect Effects 0.000 claims description 4
- 231100001143 noxa Toxicity 0.000 claims description 4
- 239000008191 permeabilizing agent Substances 0.000 claims description 4
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- 102000003829 Adenylate kinase 2 Human genes 0.000 claims description 2
- 108090000115 Adenylate kinase 2 Proteins 0.000 claims description 2
- 102000018832 Cytochromes Human genes 0.000 claims description 2
- 108010052832 Cytochromes Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims description 2
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 101100232163 Mus musculus Htra2 gene Proteins 0.000 claims description 2
- 101710129178 Outer plastidial membrane protein porin Proteins 0.000 claims description 2
- 108010090804 Streptavidin Proteins 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 102100037820 Voltage-dependent anion-selective channel protein 1 Human genes 0.000 claims description 2
- 230000001464 adherent effect Effects 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical group O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 claims description 2
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 238000000799 fluorescence microscopy Methods 0.000 claims description 2
- 238000005558 fluorometry Methods 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 238000010191 image analysis Methods 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 claims description 2
- 238000000386 microscopy Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 108010087904 neutravidin Proteins 0.000 claims description 2
- 230000008823 permeabilization Effects 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 2
- 229930182490 saponin Natural products 0.000 claims description 2
- 150000007949 saponins Chemical class 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 125000000647 trehalose group Chemical group 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153475P | 2015-04-27 | 2015-04-27 | |
| US62/153,475 | 2015-04-27 | ||
| PCT/US2016/029495 WO2016176288A1 (en) | 2015-04-27 | 2016-04-27 | High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514210A JP2018514210A (ja) | 2018-06-07 |
| JP2018514210A5 true JP2018514210A5 (https=) | 2019-07-04 |
| JP6802185B2 JP6802185B2 (ja) | 2020-12-16 |
Family
ID=57198812
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555779A Active JP6814745B2 (ja) | 2015-04-27 | 2016-04-27 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
| JP2017555780A Active JP6802185B2 (ja) | 2015-04-27 | 2016-04-27 | ハイスループットｂｈ３プロファイリング：少量の細胞でのｂｈ３プロファイルのための迅速かつ拡大縮小可能な技術 |
| JP2020200805A Withdrawn JP2021036915A (ja) | 2015-04-27 | 2020-12-03 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555779A Active JP6814745B2 (ja) | 2015-04-27 | 2016-04-27 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020200805A Withdrawn JP2021036915A (ja) | 2015-04-27 | 2020-12-03 | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10761086B2 (https=) |
| EP (2) | EP3288964B1 (https=) |
| JP (3) | JP6814745B2 (https=) |
| AU (2) | AU2016253957C1 (https=) |
| CA (1) | CA2983022C (https=) |
| WO (2) | WO2016176299A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040171809A1 (en) | 2002-09-09 | 2004-09-02 | Korsmeyer Stanley J. | BH3 peptides and method of use thereof |
| CA2645853A1 (en) | 2006-03-31 | 2007-11-01 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| JP6352924B2 (ja) | 2012-09-19 | 2018-07-04 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ダイナミックｂｈ３プロファイリング |
| AU2014323526B2 (en) | 2013-09-19 | 2020-07-23 | Dana-Farber Cancer Institute, Inc. | Methods of BH3 profiling |
| US10793915B2 (en) | 2015-01-12 | 2020-10-06 | Eutropics Pharmaceuticals, Inc. | Context dependent diagnostics test for guiding cancer treatment |
| CA2979999A1 (en) | 2015-03-18 | 2016-09-22 | Massachusetts Institute Of Technology | Selective mcl-1 binding peptides |
| HK1251655A1 (zh) | 2015-04-20 | 2019-02-01 | Tolero Pharmaceuticals, Inc. | 通过线粒体分析预测对阿伏西地的应答 |
| EP3288964B1 (en) | 2015-04-27 | 2024-02-21 | Dana-Farber Cancer Institute, Inc. | High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells |
| KR102608921B1 (ko) | 2015-05-18 | 2023-12-01 | 스미토모 파마 온콜로지, 인크. | 생체 이용률이 증가된 알보시딥 프로드러그 |
| JP7083497B2 (ja) | 2015-08-03 | 2022-06-13 | スミトモ ファーマ オンコロジー， インコーポレイテッド | がんの処置のための併用療法 |
| WO2018017922A2 (en) | 2016-07-22 | 2018-01-25 | Massachusetts Institute Of Technology | Selective bfl-1 peptides |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| AU2017379847B2 (en) | 2016-12-19 | 2022-05-26 | Sumitomo Pharma Oncology, Inc. | Profiling peptides and methods for sensitivity profiling |
| JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン |
| WO2020060975A1 (en) * | 2018-09-17 | 2020-03-26 | Massachusetts Institute Of Technology | Peptides selective for bcl-2 family proteins |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| EP3931563A4 (en) * | 2019-02-26 | 2022-12-21 | Dana-Farber Cancer Institute, Inc. | BH3 DYNAMIC PROFILING FOR LIVING CELL IMAGING |
| WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
| WO2025212653A1 (en) * | 2024-04-01 | 2025-10-09 | Dana-Farber Cancer Institute, Inc. | Methods including bh3 profiling of car t cells |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE365808T1 (de) | 1995-07-28 | 2007-07-15 | Marie Curie Cancer Care | Transportproteine und deren verwendungen |
| JP3295431B2 (ja) | 1995-10-24 | 2002-06-24 | サングスタット メディカル コーポレイション | 抗アルファ−ガラクトシルスクリーニング技術 |
| US5965703A (en) | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1015578A4 (en) | 1997-09-17 | 2004-12-01 | Walker And Eliza Hall Inst Of | THERAPEUTIC MOLECULES |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| EP1210098A1 (en) | 1999-04-07 | 2002-06-05 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
| AU6906100A (en) | 1999-08-16 | 2001-03-13 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis |
| WO2002020568A2 (en) | 2000-09-06 | 2002-03-14 | Abbott Laboratories | Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins |
| WO2002069995A2 (en) | 2001-02-16 | 2002-09-12 | Medical College Of Georgia Research Institute, Inc. | Use of trail and antiprogestins for treating cancer |
| WO2003040168A2 (en) * | 2001-11-06 | 2003-05-15 | Enanta Pharmaceuticals, Inc. | Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype |
| WO2003055515A1 (en) | 2001-12-21 | 2003-07-10 | Arius Research, Inc. | Individualized anti-cancer antibodies |
| US20040171809A1 (en) | 2002-09-09 | 2004-09-02 | Korsmeyer Stanley J. | BH3 peptides and method of use thereof |
| WO2004058804A1 (en) | 2002-12-24 | 2004-07-15 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
| EP1608969A4 (en) | 2003-03-19 | 2007-06-06 | Alfa Wassermann Inc | SEPARATION AND ACCUMULATION OF SUB-CELLULAR COMPONENTS, AND PROTEINS WHICH ARE DRAWN THEREFROM |
| ES2586387T3 (es) | 2003-11-05 | 2016-10-14 | Dana-Farber Cancer Institute, Inc. | Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular |
| WO2006069186A2 (en) | 2004-12-22 | 2006-06-29 | The Ohio State Research Foundation | Small molecule bcl-xl/bcl-2 binding inhibitors |
| JP2005130867A (ja) | 2005-02-16 | 2005-05-26 | Mitokor | ミトコンドリア内カルシウムを使用するスクリーニングアッセイ |
| WO2006099667A1 (en) | 2005-03-21 | 2006-09-28 | The Walter And Eliza Hall Institute Of Medical Research | Prophylactic and therapeutic agents and uses therefor |
| US20070027175A1 (en) | 2005-07-27 | 2007-02-01 | Shaughnessy John Jr | Antineoplastic activities of ellipticine and its derivatives |
| CA2645853A1 (en) | 2006-03-31 | 2007-11-01 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| US8518635B2 (en) | 2006-06-12 | 2013-08-27 | The J. David Gladstone Institutes | Regulation of protein activity by reversible acetylation |
| KR100786759B1 (ko) | 2006-07-07 | 2007-12-18 | 김현기 | Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물 |
| US9360473B2 (en) | 2006-08-16 | 2016-06-07 | Eutropics Pharmaceuticals, Inc. | Assay system to identify therapeutic agents |
| WO2008152405A2 (en) | 2007-06-15 | 2008-12-18 | The Queen's University Of Belfast | Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases |
| JP2011501731A (ja) | 2007-09-10 | 2011-01-13 | ユニバーシティ オブ マサチューセッツ | ミトコンドリア標的化抗腫瘍剤 |
| CA2700925C (en) | 2007-09-26 | 2016-08-23 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
| JP2009240173A (ja) | 2008-03-28 | 2009-10-22 | Univ Of Tokushima | パーキン蛋白の新規糖化因子 |
| MX2011013385A (es) | 2009-06-11 | 2012-05-29 | Minerva Biotechnologies Corp | Metodos para cultivar celulas madre y celulas progenitoras. |
| WO2010147961A1 (en) | 2009-06-15 | 2010-12-23 | Precision Therapeutics, Inc. | Methods and markers for predicting responses to chemotherapy |
| US20130122492A1 (en) | 2011-11-14 | 2013-05-16 | Kellbenx Inc. | Detection, isolation and analysis of rare cells in biological fluids |
| US20150301053A1 (en) * | 2012-05-10 | 2015-10-22 | Eutropics Pharmaceuticals, Inc. | Surrogate functional diagnostics test for cancer |
| US20150322479A1 (en) * | 2012-06-20 | 2015-11-12 | Cytospan Technologies Corporation | Apparatus and method for quantification of replicative lifespan and observation of senescene |
| JP6352924B2 (ja) | 2012-09-19 | 2018-07-04 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ダイナミックｂｈ３プロファイリング |
| JP6327662B2 (ja) | 2012-09-26 | 2018-05-23 | 学校法人藤田学園 | 細胞表面タンパクを抗原とする抗体を測定する方法 |
| EP3022222A4 (en) | 2013-07-18 | 2017-06-07 | Eutropics Pharmaceuticals, Inc. | Differential bh3 mitochondrial profiling |
| AU2014323526B2 (en) | 2013-09-19 | 2020-07-23 | Dana-Farber Cancer Institute, Inc. | Methods of BH3 profiling |
| EP3288964B1 (en) | 2015-04-27 | 2024-02-21 | Dana-Farber Cancer Institute, Inc. | High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells |
| US11092602B2 (en) | 2015-07-06 | 2021-08-17 | Whitehead Institute For Biomedical Research | Methods and compositions relating to proteasome inhibitor resistance |
| EP3931563A4 (en) | 2019-02-26 | 2022-12-21 | Dana-Farber Cancer Institute, Inc. | BH3 DYNAMIC PROFILING FOR LIVING CELL IMAGING |
-
2016
- 2016-04-27 EP EP16787039.3A patent/EP3288964B1/en active Active
- 2016-04-27 AU AU2016253957A patent/AU2016253957C1/en active Active
- 2016-04-27 US US15/568,994 patent/US10761086B2/en active Active
- 2016-04-27 WO PCT/US2016/029510 patent/WO2016176299A1/en not_active Ceased
- 2016-04-27 CA CA2983022A patent/CA2983022C/en active Active
- 2016-04-27 WO PCT/US2016/029495 patent/WO2016176288A1/en not_active Ceased
- 2016-04-27 AU AU2016255749A patent/AU2016255749B2/en active Active
- 2016-04-27 JP JP2017555779A patent/JP6814745B2/ja active Active
- 2016-04-27 US US15/569,851 patent/US20180120297A1/en not_active Abandoned
- 2016-04-27 EP EP16787045.0A patent/EP3289094B1/en active Active
- 2016-04-27 JP JP2017555780A patent/JP6802185B2/ja active Active
-
2020
- 2020-07-27 US US16/939,736 patent/US11867688B2/en active Active
- 2020-12-03 JP JP2020200805A patent/JP2021036915A/ja not_active Withdrawn
-
2021
- 2021-02-26 US US17/186,344 patent/US20210255167A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514210A5 (https=) | ||
| Mekhdjian et al. | Integrin-mediated traction force enhances paxillin molecular associations and adhesion dynamics that increase the invasiveness of tumor cells into a three-dimensional extracellular matrix | |
| US11199549B2 (en) | MEl'hods and means for diagnosing spondylarthritis using autoantibody markers | |
| ES2899191T3 (es) | Péptidos y procedimientos de detección de alergia alimentaria | |
| JP2021036915A (ja) | ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法 | |
| JP2016538545A5 (https=) | ||
| JP2015531606A5 (https=) | ||
| CA2811678C (en) | Novel method for diagnosing lyme disease using a cellular immunological test | |
| ES2664352T3 (es) | Método in vitro para evaluar respuestas de tormenta de citoquinas | |
| JP2012501631A5 (https=) | ||
| JP2022512664A (ja) | 骨髄幹細胞治療に対する応答の予測方法 | |
| CN111505285A (zh) | SARS-CoV-2检测芯片及其应用 | |
| RU2018138782A (ru) | Антитела к фактору ix padua | |
| Elkhodiry et al. | Isolating and expanding endothelial progenitor cells from peripheral blood on peptide‐functionalized polystyrene surfaces | |
| US20160252523A1 (en) | Method for removing genomically unstable ips cells and synthetic peptide used therefor | |
| JP2004500350A (ja) | 標的分子に対するリガンドを同定する方法 | |
| US8771971B2 (en) | Methods and kits for measurement of lymphocyte function | |
| Mocumbi et al. | Presence of circulating anti-myosin antibodies in endomyocardial fibrosis | |
| ES2569187T3 (es) | Biomarcadores para enfermedades hepáticas autoinmunes y usos de los mismos | |
| ES2791981T3 (es) | Método y sistema de detección de anticuerpos | |
| JP2018501820A5 (https=) | ||
| US9488645B2 (en) | Cell-based microarrays and methods of use | |
| US20180188268A1 (en) | Cardiomyocyte-Specific Biological Markers and Uses Thereof | |
| CN104374918B (zh) | 热休克蛋白47胶质瘤相关肿瘤抗原及应用 | |
| JPWO2016035677A1 (ja) | ｉｎ ｖｉｔｒｏサイクリックヌクレオチド測定の為のサンプルの前処理方法 |